Click for best price
Peripheral Tcell lymphoma Therapy Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Peripheral T-cell lymphoma Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral T-cell lymphoma Therapy. This report contains market size and forecasts of Peripheral T-cell lymphoma Therapy in global, including the following market information:
Global Peripheral T-cell lymphoma Therapy Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Peripheral T-cell lymphoma Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chidamide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Peripheral T-cell lymphoma Therapy include Antengene, Genor BioPharma Co., Ltd., Hospira (Pfizer Inc.), Dizal Pharma, Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. and Celgene Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Peripheral T-cell lymphoma Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Peripheral T-cell lymphoma Therapy Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Peripheral T-cell lymphoma Therapy Market Segment Percentages, by Type, 2022 (%)
Chidamide
Selinexor
Other
Global Peripheral T-cell lymphoma Therapy Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Peripheral T-cell lymphoma Therapy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Global Peripheral T-cell lymphoma Therapy Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Peripheral T-cell lymphoma Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peripheral T-cell lymphoma Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Peripheral T-cell lymphoma Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Antengene
Genor BioPharma Co., Ltd.
Hospira (Pfizer Inc.)
Dizal Pharma
Bristol-Myers Squibb Company
Sigma-Tau Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Celgene Corporation
Eisai Co., Ltd.
Leadiant Biosciences
Merck
Genmab AS
HUYABIO International
Outline of Major Chapters:
Chapter 1: Introduces the definition of Peripheral T-cell lymphoma Therapy, market overview.
Chapter 2: Global Peripheral T-cell lymphoma Therapy market size in revenue.
Chapter 3: Detailed analysis of Peripheral T-cell lymphoma Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peripheral T-cell lymphoma Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Peripheral T-cell lymphoma Therapy Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
69 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Peripheral T-cell lymphoma Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Peripheral T-cell lymphoma Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Peripheral T-cell lymphoma Therapy Overall Market Size
2.1 Global Peripheral T-cell lymphoma Therapy Market Size: 2022 VS 2032
2.2 Global Peripheral T-cell lymphoma Therapy Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Peripheral T-cell lymphoma Therapy Players in Global Market
3.2 Top Global Peripheral T-cell lymphoma Therapy Companies Ranked by Revenue
3.3 Global Peripheral T-cell lymphoma Therapy Revenue by Companies
3.4 Top 3 and Top 5 Peripheral T-cell lymphoma Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Peripheral T-cell lymphoma Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Peripheral T-cell lymphoma Therapy Players in Global Market
3.6.1 List of Global Tier 1 Peripheral T-cell lymphoma Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Peripheral T-cell lymphoma Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Peripheral T-cell lymphoma Therapy Market Size Markets, 2022 & 2032
4.1.2 Chidamide
4.1.3 Selinexor
4.1.4 Other
4.2 By Type - Global Peripheral T-cell lymphoma Therapy Revenue & Forecasts
4.2.1 By Type - Global Peripheral T-cell lymphoma Therapy Revenue, 2018-2023
4.2.2 By Type - Global Peripheral T-cell lymphoma Therapy Revenue, 2024-2032
4.2.3 By Type - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Peripheral T-cell lymphoma Therapy Market Size, 2022 & 2032
5.1.2 Hospitals
5.1.3 Clinics
5.2 By Application - Global Peripheral T-cell lymphoma Therapy Revenue & Forecasts
5.2.1 By Application - Global Peripheral T-cell lymphoma Therapy Revenue, 2018-2023
5.2.2 By Application - Global Peripheral T-cell lymphoma Therapy Revenue, 2024-2032
5.2.3 By Application - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Peripheral T-cell lymphoma Therapy Market Size, 2022 & 2032
6.2 By Region - Global Peripheral T-cell lymphoma Therapy Revenue & Forecasts
6.2.1 By Region - Global Peripheral T-cell lymphoma Therapy Revenue, 2018-2023
6.2.2 By Region - Global Peripheral T-cell lymphoma Therapy Revenue, 2024-2032
6.2.3 By Region - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Peripheral T-cell lymphoma Therapy Revenue, 2018-2032
6.3.2 US Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.3.3 Canada Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.3.4 Mexico Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Peripheral T-cell lymphoma Therapy Revenue, 2018-2032
6.4.2 Germany Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.3 France Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.4 U.K. Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.5 Italy Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.6 Russia Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.7 Nordic Countries Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.4.8 Benelux Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Peripheral T-cell lymphoma Therapy Revenue, 2018-2032
6.5.2 China Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.5.3 Japan Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.5.4 South Korea Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.5.5 Southeast Asia Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.5.6 India Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Peripheral T-cell lymphoma Therapy Revenue, 2018-2032
6.6.2 Brazil Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.6.3 Argentina Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Peripheral T-cell lymphoma Therapy Revenue, 2018-2032
6.7.2 Turkey Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.7.3 Israel Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.7.4 Saudi Arabia Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
6.7.5 UAE Peripheral T-cell lymphoma Therapy Market Size, 2018-2032
7 Peripheral T-cell lymphoma Therapy Companies Profiles
7.1 Antengene
7.1.1 Antengene Company Summary
7.1.2 Antengene Business Overview
7.1.3 Antengene Peripheral T-cell lymphoma Therapy Major Product Offerings
7.1.4 Antengene Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.1.5 Antengene Key News & Latest Developments
7.2 Genor BioPharma Co., Ltd.
7.2.1 Genor BioPharma Co., Ltd. Company Summary
7.2.2 Genor BioPharma Co., Ltd. Business Overview
7.2.3 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Major Product Offerings
7.2.4 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.2.5 Genor BioPharma Co., Ltd. Key News & Latest Developments
7.3 Hospira (Pfizer Inc.)
7.3.1 Hospira (Pfizer Inc.) Company Summary
7.3.2 Hospira (Pfizer Inc.) Business Overview
7.3.3 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Major Product Offerings
7.3.4 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.3.5 Hospira (Pfizer Inc.) Key News & Latest Developments
7.4 Dizal Pharma
7.4.1 Dizal Pharma Company Summary
7.4.2 Dizal Pharma Business Overview
7.4.3 Dizal Pharma Peripheral T-cell lymphoma Therapy Major Product Offerings
7.4.4 Dizal Pharma Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.4.5 Dizal Pharma Key News & Latest Developments
7.5 Bristol-Myers Squibb Company
7.5.1 Bristol-Myers Squibb Company Company Summary
7.5.2 Bristol-Myers Squibb Company Business Overview
7.5.3 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Major Product Offerings
7.5.4 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.6 Sigma-Tau Pharmaceuticals, Inc.
7.6.1 Sigma-Tau Pharmaceuticals, Inc. Company Summary
7.6.2 Sigma-Tau Pharmaceuticals, Inc. Business Overview
7.6.3 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Major Product Offerings
7.6.4 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.6.5 Sigma-Tau Pharmaceuticals, Inc. Key News & Latest Developments
7.7 Pacira Pharmaceuticals, Inc.
7.7.1 Pacira Pharmaceuticals, Inc. Company Summary
7.7.2 Pacira Pharmaceuticals, Inc. Business Overview
7.7.3 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Major Product Offerings
7.7.4 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.7.5 Pacira Pharmaceuticals, Inc. Key News & Latest Developments
7.8 Spectrum Pharmaceuticals, Inc.
7.8.1 Spectrum Pharmaceuticals, Inc. Company Summary
7.8.2 Spectrum Pharmaceuticals, Inc. Business Overview
7.8.3 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Major Product Offerings
7.8.4 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.8.5 Spectrum Pharmaceuticals, Inc. Key News & Latest Developments
7.9 Celgene Corporation
7.9.1 Celgene Corporation Company Summary
7.9.2 Celgene Corporation Business Overview
7.9.3 Celgene Corporation Peripheral T-cell lymphoma Therapy Major Product Offerings
7.9.4 Celgene Corporation Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.9.5 Celgene Corporation Key News & Latest Developments
7.10 Eisai Co., Ltd.
7.10.1 Eisai Co., Ltd. Company Summary
7.10.2 Eisai Co., Ltd. Business Overview
7.10.3 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Major Product Offerings
7.10.4 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.10.5 Eisai Co., Ltd. Key News & Latest Developments
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Company Summary
7.11.2 Leadiant Biosciences Business Overview
7.11.3 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Major Product Offerings
7.11.4 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.11.5 Leadiant Biosciences Key News & Latest Developments
7.12 Merck
7.12.1 Merck Company Summary
7.12.2 Merck Business Overview
7.12.3 Merck Peripheral T-cell lymphoma Therapy Major Product Offerings
7.12.4 Merck Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.12.5 Merck Key News & Latest Developments
7.13 Genmab AS
7.13.1 Genmab AS Company Summary
7.13.2 Genmab AS Business Overview
7.13.3 Genmab AS Peripheral T-cell lymphoma Therapy Major Product Offerings
7.13.4 Genmab AS Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.13.5 Genmab AS Key News & Latest Developments
7.14 HUYABIO International
7.14.1 HUYABIO International Company Summary
7.14.2 HUYABIO International Business Overview
7.14.3 HUYABIO International Peripheral T-cell lymphoma Therapy Major Product Offerings
7.14.4 HUYABIO International Peripheral T-cell lymphoma Therapy Revenue in Global Market (2018-2023)
7.14.5 HUYABIO International Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Peripheral T-cell lymphoma Therapy Market Opportunities & Trends in Global Market
Table 2. Peripheral T-cell lymphoma Therapy Market Drivers in Global Market
Table 3. Peripheral T-cell lymphoma Therapy Market Restraints in Global Market
Table 4. Key Players of Peripheral T-cell lymphoma Therapy in Global Market
Table 5. Top Peripheral T-cell lymphoma Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Peripheral T-cell lymphoma Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Peripheral T-cell lymphoma Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Peripheral T-cell lymphoma Therapy Product Type
Table 9. List of Global Tier 1 Peripheral T-cell lymphoma Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Peripheral T-cell lymphoma Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Peripheral T-cell lymphoma Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Peripheral T-cell lymphoma Therapy Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Peripheral T-cell lymphoma Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Peripheral T-cell lymphoma Therapy Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Peripheral T-cell lymphoma Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Peripheral T-cell lymphoma Therapy Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2024-2032
Table 30. Antengene Company Summary
Table 31. Antengene Peripheral T-cell lymphoma Therapy Product Offerings
Table 32. Antengene Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Antengene Key News & Latest Developments
Table 34. Genor BioPharma Co., Ltd. Company Summary
Table 35. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product Offerings
Table 36. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Genor BioPharma Co., Ltd. Key News & Latest Developments
Table 38. Hospira (Pfizer Inc.) Company Summary
Table 39. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product Offerings
Table 40. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Hospira (Pfizer Inc.) Key News & Latest Developments
Table 42. Dizal Pharma Company Summary
Table 43. Dizal Pharma Peripheral T-cell lymphoma Therapy Product Offerings
Table 44. Dizal Pharma Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Dizal Pharma Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Company Summary
Table 47. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product Offerings
Table 48. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Company Key News & Latest Developments
Table 50. Sigma-Tau Pharmaceuticals, Inc. Company Summary
Table 51. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product Offerings
Table 52. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Sigma-Tau Pharmaceuticals, Inc. Key News & Latest Developments
Table 54. Pacira Pharmaceuticals, Inc. Company Summary
Table 55. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product Offerings
Table 56. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. Pacira Pharmaceuticals, Inc. Key News & Latest Developments
Table 58. Spectrum Pharmaceuticals, Inc. Company Summary
Table 59. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product Offerings
Table 60. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Spectrum Pharmaceuticals, Inc. Key News & Latest Developments
Table 62. Celgene Corporation Company Summary
Table 63. Celgene Corporation Peripheral T-cell lymphoma Therapy Product Offerings
Table 64. Celgene Corporation Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. Celgene Corporation Key News & Latest Developments
Table 66. Eisai Co., Ltd. Company Summary
Table 67. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product Offerings
Table 68. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Eisai Co., Ltd. Key News & Latest Developments
Table 70. Leadiant Biosciences Company Summary
Table 71. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product Offerings
Table 72. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Leadiant Biosciences Key News & Latest Developments
Table 74. Merck Company Summary
Table 75. Merck Peripheral T-cell lymphoma Therapy Product Offerings
Table 76. Merck Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Merck Key News & Latest Developments
Table 78. Genmab AS Company Summary
Table 79. Genmab AS Peripheral T-cell lymphoma Therapy Product Offerings
Table 80. Genmab AS Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 81. Genmab AS Key News & Latest Developments
Table 82. HUYABIO International Company Summary
Table 83. HUYABIO International Peripheral T-cell lymphoma Therapy Product Offerings
Table 84. HUYABIO International Peripheral T-cell lymphoma Therapy Revenue (US$, Mn) & (2018-2023)
Table 85. HUYABIO International Key News & Latest Developments
List of Figures
Figure 1. Peripheral T-cell lymphoma Therapy Segment by Type in 2022
Figure 2. Peripheral T-cell lymphoma Therapy Segment by Application in 2022
Figure 3. Global Peripheral T-cell lymphoma Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Peripheral T-cell lymphoma Therapy Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Peripheral T-cell lymphoma Therapy Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Peripheral T-cell lymphoma Therapy Revenue in 2022
Figure 8. By Type - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 9. By Application - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 10. By Type - Global Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 12. By Application - Global Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 14. By Region - Global Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 15. By Country - North America Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 16. US Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 20. Germany Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 21. France Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 28. China Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 32. India Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 34. Brazil Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Peripheral T-cell lymphoma Therapy Revenue Market Share, 2018-2032
Figure 37. Turkey Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Peripheral T-cell lymphoma Therapy Revenue, (US$, Mn), 2018-2032
Figure 41. Antengene Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Dizal Pharma Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Celgene Corporation Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Merck Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Genmab AS Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. HUYABIO International Peripheral T-cell lymphoma Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
